ClinicalTrials.gg
TerminatedNCT02806141Updated Aug 2, 2018

Aerosolized Plus Intravenous vs. Intravenous Colistin for VAP Due to Pandrugs-resistant A. Baumannii in Neonates

A Phase 3 interventional study of Aerosolized plus intravenous colistin and Intravenous colistin in Pneumonia, Ventilator-Associated, Colistin Adverse Reaction and Infection Due to Multidrug Resistant Acinetobacter, sponsored by Hat Yai Medical Education Center. Terminated at 1 site in Thailand. Open to participants aged 1 Day to 30 Days. Per ClinicalTrials.gov, last updated 2018-08-02.

Sponsored by Hat Yai Medical Education Center · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
No patient included at target sample sizes

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
1 Day to 30 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Pneumonia, Ventilator-Associated with a site in Thailand — 1 open to participants now, 1 under way, none of them phase 3. Pneumonia, Ventilator-Associated · Thailand.

Enrollment
6th of 14
204 · median 106
Started
2016
with 1 other
Phase 3
5 of 14
none open now
Registered
10th of 14
by date
Lead sponsor
1 of 14
Hat Yai Medical Education Center

Among the 14 studies in Pneumonia, Ventilator-Associated with a site in Thailand, this one is the 6th largest by enrollment, is one of 2 that started in 2016, is one of 5 in phase 3, and was the 10th registered.

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

Browse Pneumonia, Ventilator-Associated studies →

Open to participants now

1 of the 14 studies in Pneumonia, Ventilator-Associated with a site in Thailand is open now. Recruiting first, the newest first:

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 1 Day to 30 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Pneumonia, Ventilator-Associated with a site in Thailand, or all of them as a file.
02

Study summary

This study is planned to compare the clinical efficacy and safety of aerosolized plus intravenous colistin vs. intravenous colistin as adjunctive therapy for the treatment of ventilator-associated pneumonia (VAP) due to pandrugs-resistant (PDR) Acinetobacter baumannii in the neonates.

Read the detailed description

This study will evaluate the neonates with VAP due to PDR-Acinetobacter baumannii who receive aerosolized plus intravenous colistin compare with intravenous colistin as adjunctive therapy. The efficacy and safety after study will be evaluated.

03

Conditions studied

  • Pneumonia, Ventilator-Associated
  • Colistin Adverse Reaction
  • Infection Due to Multidrug Resistant Acinetobacter
  • Infection Resistant to Multiple Drugs

Keywords

  • Aerosolized colistin
  • Intravenous colistin
04

Who can participate

Ages eligible
1 Day to 30 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Neonates who are admitted to the neonatal intensive care unit, Hat Yai Hospital during the study period.
  • Neonates who were complicated with VAP due to PDR-Acinetobacter baumannii susceptible to colistin (by minimal inhibitory concentration (MIC) \< 2 mcg/dL).

Exclusion criteria

Exclusion Criteria:

  • Neonates who have a major anomaly or chromosomal abnormality.
  • Neonates who receive colistin prior 7 days prior to study.
  • Neonates who have a significant renal dysfunction defined as a serum creatinine (SCr) >1.5 mg/dL or a decrease in urine output to \< 1 mL/kg/h;
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
204 participants (actual)

Study arms

  • Experimental
    Aerosolized plus intravenous colistin

    Neonates with VAP due to PDR-A. baumannii who receive aerosolized colistin (4 mg/kg/dose twice daily) plus intravenous colistin (3.5 mg/kg/dose twice daily)

    Drug: Aerosolized plus intravenous colistin

  • Active comparator
    Intravenous colistin

    Neonates with VAP due to PDR-A. baumannii who receive only intravenous colistin (3.5 mg/kg/dose twice daily)

    Drug: Intravenous colistin

Interventions

  • DrugAerosolized plus intravenous colistin

    Drug page: Colistinmethanesulfonic acidStudies of Colistinmethanesulfonic acidColistinmethanesulfonic acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Aerosolized colistin at the dose of 4 mg colistin base activity (CBA)/kg twice daily (8 mg/kg/day) plus intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)

    Also known as: colistimethate sodium

  • DrugColistinStudies of ColistinColistin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)

    Also known as: colistimethate sodium

06

What researchers measure

Primary outcomes

  1. Number of Patients With Cure

    Clinical outcome is classified in 4 categories: Cure, Improved, Failure, and Death

    Time frame: Through study completion, an average of 2 weeks

  2. Number of Patients With Improved

    Clinical outcome is classified in 4 categories: Cure, Improved, Failure, and Death

    Time frame: Through study completion, an average of 2 weeks

  3. Number of Patients With Failure

    Clinical outcome is classified in 4 categories: Cure, Improved, Failure, and Death

    Time frame: Through study completion, an average of 2 weeks

  4. Number of Patients With Death

    Clinical outcome is classified in 4 categories: Cure, Improved, Failure, and Death

    Time frame: Through study completion, an average of 2 weeks

Secondary outcomes

  1. Number of Patients With Eradication

    Microbiological response is classified in 3 categories: Eradication Persistence, Superinfection

    Time frame: Through study completion, an average of 2 weeks

  2. Number of Patients With Persistence

    Microbiological response is classified in 3 categories: Eradication Persistence, Superinfection

    Time frame: Through study completion, an average of 2 weeks

  3. Number of Patients With Superinfection

    Microbiological response is classified in 3 categories: Eradication Persistence, Superinfection

    Time frame: Through study completion, an average of 2 weeks

  4. Number of Patients With Adverse Events That Are Related to Study Drug

    Number of Patients With Adverse Events That Are Related to Study Drug, Graded According to NCI CTCAE Version 3.0 focus on neurology, pulmonology, nephrology and metabolic/laboratory.

    Time frame: Through study completion, an average of 4 weeks

07

Study locations

1 site
  • Narongsak Nakwan
    Hat Yai, Songkhla 90110, Thailand
08

References and documents

Publications

  • Nakwan N, Wannaro J, Thongmak T, Pornladnum P, Saksawad R, Nakwan N, Chokephaibulkit K. Safety in treatment of ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii with aerosolized colistin in neonates: a preliminary report. Pediatr Pulmonol. 2011 Jan;46(1):60-6. doi: 10.1002/ppul.21324. Epub 2010 Sep 1. PubMed 20812247 ↗
  • Nakwan N, Lertpichaluk P, Chokephaibulkit K, Villani P, Regazzi M, Imberti R. Pulmonary and Systemic Pharmacokinetics of Colistin Following a Single Dose of Nebulized Colistimethate in Mechanically Ventilated Neonates. Pediatr Infect Dis J. 2015 Sep;34(9):961-3. doi: 10.1097/INF.0000000000000775. PubMed 26065861 ↗
  • Nakwan N, Usaha S, Chokephaibulkit K, Villani P, Regazzi M, Imberti R. Pharmacokinetics of Colistin Following a Single Dose of Intravenous Colistimethate Sodium in Critically Ill Neonates. Pediatr Infect Dis J. 2016 Nov;35(11):1211-1214. doi: 10.1097/INF.0000000000001263. PubMed 27276179 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2016, a primary completion of Oct 2017 and a completion of Oct 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2016
First posted
Jun 20, 2016
Start
Sep 2016
Primary completionActual
Oct 2017
CompletionActual
Oct 2017
Last update
Aug 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02806141
Lead sponsor
Hat Yai Medical Education Center
Responsible party
Dr. Narongsak Nakwan (Head of Division of Neonatalogy, Department of Pediatrics, Hat Yai Hospital, Hat Yai Medical Education Center) — Principal investigator
First posted
Jun 20, 2016
Start date
Sep 2016
Primary completion
Oct 2017
Completion
Oct 2017
Last update
Aug 2, 2018

Study contacts

Narongsak Nakwan, MD
principal investigator · Hat Yai Medical Education Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Colistinmethanesulfonic acid

Start the discussion